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Abstract
BACKGROUND: The aim of this study was to evaluate the 
cardiac sympathetic nervous system function in haemodialysed 
(HD), non-diabetic patients by iodine-123 meta-iodo-benzyl-
guanidine (123I-mIBG). 
MATERIALS AND METHODS: Planar scintigraphy of the chest 
was performed in 36 HD, male patients; 15 minutes and 4 hours 
post injection of 370 MBq of 123I-mIBG. The semiquantitative 
analysis of myocardial tracer uptake was expressed as routine 
heart to mediastinum (H/M) ratio: 15 minutes (early H/M) and 
4 hour (late H/M) post administration as well as washout of the 
tracer from myocardium (WR). 24-hour Holter studies were re-
corded and heart rate variability (HRV) was evaluated. Patients 
were divided into two groups according to the H/M value: group 
A patients with H/M > 1.8 which has been accepted as a norm, 
and group B patients with H/M < 1.8.
RESULTS: In 21/36 patients H/M ratio was below normal values. 
Significant differences between groups A and B were found 
among the following parameters: early H/M and late H/M ratios, 
WR and duration of haemodialysis therapy. 
CONCLUSIONS: In patients with abnormal function of cardiac 
sympathetic nervous system, expressed by means of H/M ratio 
below 1.8, duration of haemodialysis treatment was longer. 
Duration of HD appears to be an important factor influencing 
cardiac sympathetic nervous system. 
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Background 
In the Central Europe, the number of patients treated by renal 
replacement therapy has doubled every decade since 1980 [1]. In 
countries with low rate of renal transplant procedures, complica-
tions accompanying with long-term haemodialysis (HD) therapy 
are often observed. Among them, the cardiovascular complica-
tions are the leading cause of death, accounting at least 40% 
of deaths in end-stage renal disease (ESRD), 20% of which are 
sudden [2]. The hyperactivity of the cardiac sympathetic ner-
vous system (CSNS) is observed in all stages of chronic renal 
disease (CRD) [3]. The CSNS function can be partly improved 
along with duration of dialysis [4] or after renal transplant [5]. 
But, despite the effectiveness of dialysis, circulating uremia-re-
lated toxins cause excitation of renal afferent nerves and activate 
CSNS [6]. Overhydration as well as accumulation of uremic 
toxins stimulate development of the left ventricular hypertrophy 
and dysfunction [2]. Nuclear medicine procedures are the only 
imaging modalities which enable in vivo visualization of global 
and regional cardiac CSNS functions. Iodine-123 meta-iodo-ben-
zylguanidine (123I-mIBG) SPECT depicts presynaptic uptake and 
storage of radiolabelled neurotransmitter [7, 8]. It is well known, 
that dysfunction of CSNS is enhanced in diabetic patients, where 
diabetes mellitus (DM) is the most frequent cause of nephropa-
thy [9, 10]. However, the current report specifically evaluates the 
CSNS function in haemodialysed (HD), non-diabetic patients by 
iodine-123 meta-iodo-benzylguanidine (123I-mIBG). 
Materials and methods
Study population
The study group comprised 36 HD male patients (aged 
29–79; 54.7 ± 12.3 years). All had HD sessions three times per 
week. Patients in poor general condition, unable to exercise, with 
DM, amyloidosis, dialysis-induced hypotension and neoplastic 
diseases were excluded from the study. The underlying cause 
of renal failure was chronic glomerulonephritis (18 patients) and 
other miscellaneous causes (18 patients). Patients who receive 
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drugs that might affect cardiac sympathetic system (e.g. tricyclic 
antidepressants, sympathetic agents) were not included. An 
antihypertensive medications such as angiotensin converting 
enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) 
in patients with hypertension were not withdrawn before 123I-mIBG 
scintigraphy, as suggested by Flotas et al. [11]. 
123I-mIBG myocardial uptake 
Cardiac adrenergic system was evaluated on the day without 
HD sessions, at rest conditions, after IV injection of 370 MBq 
123I-mIBG. The anterior planar images of the chest were performed 
on double-head, large field of view gamma camera Varicam (Els-
cint, Haifa, Israel), in two stages: after 15 minutes (early imaging) 
and after 4 hours (late imaging) post injection. In all studies 15% 
energy window was set symmetrically at 159 keV and low-energy 
high-resolution collimators were used. The images were col-
lected on 128 x 128 matrix for 400 seconds. The 123I-mIBG uptake 
was evaluated semiquantitatively by calculation of heart to medi-
astinum (H/M) ratio and myocardial washout rate (WR) according 
to EANM proposed standard [11] and to previously described 
methods [12]. To calculate H/M ratio, two regions of interest (ROI) 
in anterior planar image were determined. The ROI of the heart 
(H) was irregular, drawn over the entire outline of the heart and 
its size depending on the patient. The ROI of the mediastinum 
(M), was rectangle, 7 ¥ 7 pixels in size, selected from the central 
superior mediastinum sector (Figure 1). The H/M was calculated 
from early and late imaging as follows: 
H/M =
mean count per pixel in heart R01(H)
Mean count per pixel in mediastinum R01 (M)
The myocardial WR was expressed as decreasing myocardial 
activity over time between early and late imaging, normalized to 
mediastinal activity [11] in the following manner:
WR =
 early imaging (H – M) – late imaging (H – M) 
¥ 100%
early imaging (H – M) 
Cardiac sympathetic nervous system was considered to be 
dysfunctional if H/M ratio was below 1.8 [7, 10, 13]. According 
this value patients were divided into two groups: group A with 
normal function of CSNS and group B with impaired CSNS func-
tion (Table 1).
Table 1. The comparison of studied parameters within group A and B
Parameters
Group A; n = 15 Group B; n = 21
P*Median Minimum Maximum Median Minimum Maximum
Age (years) 53 29 69 58 36 79 NS
mHD (months) 12 4 108 53 7 132 0.03
Duration of hypertension (months) 24 4 120 25 0 120 NS
Body mass index [kg/m2] 23.3 15.9 30.7 24.3 18 36.2 NS
Calcium [mg/dl] 8.8 8.1 10 8.7 7.84 10 NS
Phosphate [mg/dl] 5.1 3.2 7.7 4.6 2.25 7.6 NS
Calcium-phosphate product 45.6 30 62 44 16 66.12 NS
Parathyroid hormone [mg/dl] 301 135 794 421 29 2670 NS
Haemoglobin [mg/dl] 11.2 9.7 13.2 11.2 9.1 13.7 NS
Serum albumin [mg/dl] 3.99 3.5 4.3 3.9 3.5 4.38 NS
KtV** 1.48 1.27 1.76 1.47 1.03 1.89 NS
Early H/M 1.93 1.8 2.44 1.74 1.37 1.76 0.01
Late H/M 1.89 1.8 2.24 1.59 1.18 1.70 0.001
Washout rate (WR) 22.19 17.42 27.25 40.01 29.56 69.15 0.001
Heart rate variability [ms] (SDNN) 108 79 160 85 53 201 NS
*Mann-Whitney test; **Kt/V — marker of dialysis adequacy; K — clearance; t — time; V — volume; H/M — heart to mediastinum ratio; NS — not significant
Figure 1. I-123 mIBG planar anterior projection of the thorax with 
examples of the heart (H) and mediastinum (M) ROI
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Heart rate variability (HRV) 
In all patients a 24-hour ambulatory Holter recordings were 
performed using OXFORD CardioScan Suprima 12 system. For 
time-domain heart rate variability (HRV) measures, the standard 
deviation of normal-to-normal R-R intervals (SDNN) obtained dur-
ing 24 hours were calculated. 
Statistical analysis
All calculations were expressed as median, minimal and 
maximal values. The differences between the study groups were 
assessed with Mann-Whitney test; p value < 0.05 was considered 
to indicate statistical significance. Data was analyzed using SPSS 
16.0 (SPSS Inc., Chicago, IL) statistical software. 
Ethics 
Each of the patients signed an informed consent form. The 
study protocol and informed consent forms were approved by The 
Bioethical Council, Medical University of Lublin, Poland. The test 
was well tolerated by all of the patients.
Results 
The semiquantitative evaluation of 123I-mIBG myocardial uptake 
revealed abnormal (lower than 1.8) value of early and late H/M ratio 
in 21 (58%) out of 36 patients (B group). Normal values were found 
in 15 (42%) of 36 patients (group A). There were significant differ-
ences between group A and B among this indices. The values of 
myocardial WR were significantly higher in group B compare with 
A. Moreover the duration of haemodialysis therapy in patients in 
group B was significantly longer than in group A. The heart rate 
variability, expressed by SDNN was not significantly different 
between groups A and B (Table 1).
Discussion and conclusions 
The uremic changes in the circulatory system leads to the heart 
failure, the main cause of death in CRD. Dysfunction of CSNS 
largely influences presentation of cardiovascular complications in 
HD patients. The major cardiac events (MCE) often occur within 
the first year of HD [14–16]. Nevertheless, HD patients are often 
undiagnosed with abnormal cardiac sympathetic nervous system 
function. 
In current study, patients were divided into two groups ac-
cording to the H/M value, where 1.8 was considered as a normal, 
based on previous studies performed in similar method [10, 13, 
17]. Patients with DM and amyloidosis were excluded from our 
study, because of evident influence on CSNS [9, 13, 18, 19–21]. 
The semiquantified evaluation of 123I-mIBG myocardial uptake 
was expressed as early and late H/M ratios as well as WR. The early 
H/M ratio reflects the integrity of pre-synaptic nerve endings and 
neuronal uptake of neurotransmitters, whereas the late H/M ratio 
combines information on neuronal function from uptake to release 
through the storage vesicle at the nerve endings. This functionality 
were impaired in 58% of studied patients. The value of both: early 
and late H/M ratios in group B were significantly lower than in group 
A. But, values of both early and late H/M ratios in group B were 
not as low as 1.2, which value indicated patients with high risk of 
cardiovascular death [22]. Myocardial 123I-mIBG WR is an index 
of the degree of sympathetic tone. The increased CSNS activity 
manifests as high myocardial WR and low late uptake of 123I-mIBG. 
It is considered as the poor prognostic factor of major cardiac 
events [23, 24]. The normal WR values range from 20% ± 10% [25]. 
In our patients this index exceeded normal value only in group B, 
whereas in group A the maximal value came to 27.25. According 
to Kioka et al. the value of myocardial WR higher or equal than 
27% is the only independent predictor of sudden cardiac death 
(SCD) [26]. Our main fining is that, in patients with abnormal H/M 
ratio, which reflects sympathetic function, the duration of haemo-
dialysis is significantly longer in comparison with patients with 
normal H/M ratio.  
Decreased HRV, reflected by low values of SDNN in 24-hour 
Holter monitoring (especially below 50 ms) identifies patients at 
an increased risk for SCD, which is also proven in the population 
of HD patients [27, 28]. In group B, the minimal value of SDNN 
was close to 50, but there is no significant different in HRV between 
groups A and B, similarly to other authors [13]. 
The semiquantitative assessment of 123I-mIBG myocardial 
uptake is an important tool in evaluation of the cardiac sympa-
thetic nervous system function. This function may deteriorate with 
duration of haemodialysis. It has been found that, in patients with 
abnormal function of cardiac sympathetic nervous system, ex-
pressed by means of lower than 1.8 H/M ratio, duration of hae-
modialysis treatment was longer. It brings us to conclusion that 
duration of haemodialysis treatment appears to be an important 
factor influencing cardiac sympathetic nervous system. The H/M 
ratios and WR are more sensitive indices of CSNS damage than 
heart rate variability. 
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